Skip to main content

Biogen Inc(BIIB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low183.17
Day High186.65
Open:186.65
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

The sectors that could see better earnings from the Iran war

So far, season two of Trade Off has highlighted how volatility can skew performance in the short run
Tipranks
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Thermo Fisher (TMO) and Biogen (BIIB)
StockStory
3 Profitable Stocks We Steer Clear Of
BYD
Motley Fool
Biogen (BIIB) Q4 2024 Earnings Call Transcript
Motley Fool
Biogen (BIIB) Q3 2024 Earnings Transcript
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Nektar Therapeutics (NKTR) and GE Healthcare Technologies Inc (GEHC)
Tipranks
Barclays Reaffirms Their Hold Rating on Biogen (BIIB)
Motley Fool
Biogen (BIIB) Q2 2025 Earnings Transcript
StockStory
Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen
CDNS
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), Biogen (BIIB)
StockStory
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
BIIB
StockStory
Biogen (BIIB) Stock Trades Up, Here Is Why
BIIB
Zacks Investment Research
Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio
Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio
GlobeNewswire
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Tipranks
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Immunovant (IMVT) and Biogen (BIIB)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Nkarta (NKTX)
Zacks Investment Research
Zacks.com featured highlights include Biogen, TE Connectivity and ZTO Express (Cayman)
Zacks.com featured highlights include Biogen, TE Connectivity and ZTO Express (Cayman)
Zacks Investment Research
3 Stocks With Upgraded Broker Ratings As Markets Hit All-Time High
3 Stocks With Upgraded Broker Ratings As Markets Hit All-Time High
Motley Fool
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?
Zacks Investment Research
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
Tipranks
Biogen price target raised to $200 from $190 at Morgan Stanley
Tipranks
Morgan Stanley Keeps Their Hold Rating on Biogen (BIIB)
StockStory
1 S&P 500 Stock for Long-Term Investors and 2 We Ignore
TDY
StockStory
1 Mid-Cap Stock with Promising Prospects and 2 We Brush Off
MDB
Motley Fool
Why Biogen Stock Got Mashed on Monday
Zacks Investment Research
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Tipranks
Stifel Nicolaus Keeps Their Buy Rating on Biogen (BIIB)
Tipranks
Wedbush Keeps Their Hold Rating on Biogen (BIIB)
Tipranks
Analysts Conflicted on These Healthcare Names: Gossamer Bio (GOSS) and Biogen (BIIB)
StockStory
1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down
GDDY
StockStory
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
HIMS
Tipranks
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Oric Pharmaceuticals (ORIC) and Biogen (BIIB)
Tipranks
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX)

Profile

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.